GlassScriptPhysician profile
Mohammad Qasim
NPI 1609875087
$4,756.61
in general payments reported to CMS, 2019-2025
62 companies · $1,807 in 2025
The $1,807 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $316 · 2021: $11.97 · 2022: $308 · 2023: $308 · 2024: $957 · 2025: $1,807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,071.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $567.21 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $261.76 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $230.82 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $219.80 | 2019-2025 | Calquence |
| E.R. Squibb & Sons, L.L.C. | $195.13 | 2019-2025 | Opdivo, Zeposia |
| Janssen Biotech, INC. | $170.74 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Emd Serono, INC. | $158.73 | 2019-2025 | |
| Array Biopharma INC | $157.17 | 2024-2025 | Braftovi, Mektovi, Xalkori |
| Seagen INC. | $156.76 | 2019-2022 | |
| Abbvie INC. | $155.86 | 2024-2025 | |
| Incyte Corporation | $151.85 | 2019-2025 | Jakafi |
| Genentech USA, INC. | $148.26 | 2019-2025 | Polivy, Venclexta, Tecentriq |
| Lilly USA, LLC | $145.53 | 2019-2025 | Jaypirca, Verzenio |
| Gilead Sciences, INC. | $136.52 | 2019-2025 | Trodelvy |
| Astellas Pharma US INC | $122.84 | 2019-2025 | Vyloy, Padcev |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Qasim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.